Cover Image
Market Research Report

Biosimilars Market: By Product (Recombinant Glycosated Proteins and Others) Technology (mAbs, Chromatography, Mass Spectroscopy and Others); By Application (Blood & Oncology Diseases, Chronic Diseases and Others); By Geography-Forecast (2016 - 2021)

Published by IndustryARC Product code 409046
Published Content info 152 Pages
Delivery time: 1-2 business days
Price
Back to Top
Biosimilars Market: By Product (Recombinant Glycosated Proteins and Others) Technology (mAbs, Chromatography, Mass Spectroscopy and Others); By Application (Blood & Oncology Diseases, Chronic Diseases and Others); By Geography-Forecast (2016 - 2021)
Published: July 11, 2016 Content info: 152 Pages
Description

Biosimilars are subsequent entry biologics (SEB) which are introduced into the market as the original biologic approaches patent expiry. Unlike the biologics, biosimilars are expressed in living cells which brings variability in the properties of the biosimilars. Hence, they possess properties similar to the biologic instead of being an exact copy of the original drug.

Biosimilars are emerging as one of the most important sector in the healthcare industry. With increasing healthcare costs, biosimilars are looked upon as an affordable treatment option. The report explains that global biosimilars market is segmented on the basis of product types, technology, application and geography.

Based on the technologies commercially available as biosimilars, the market is segmented as:

  • Monoclonal Antibodies Technology
  • Recombinant DNA Technology
  • Chromatography
  • Nuclear Magnetic Resonance Technology
  • Electrophoresis
  • Mass Spectrometry
  • Western Blotting
  • Bioassay

Based on product types, biosimilars are classified into Recombinant Non-Glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides while their applications include Blood Disorders, Oncology Disease, Chronic and Autoimmune Diseases along with Growth Hormone Deficiency under Others category. Each of these segments is further broken down to give an in-depth analysis of the market across various applications and covers the market demand with respect to regions.

The Biosimilars market is driven by increased demand from the application sector such as blood disorders, oncology diseases, chronic diseases and many others. Economic turmoil in Europe is yet another factor which adds to the demand for biosimilars market. Reverse Innovation will drive down the overall development costs and hence, the high discounting on biosimilars will motivate the patient to opt for it in the long run.

The developed markets such as the U.S. and Europe have been the forefront runner. Majority of drugs are currently being developed in these regions. In today's emerging markets, biosimilars are still nascent, with little to no presence. The growing investor confidence, pressure to reduce costs and discounting is driving the market. On the contrary, lack of awareness and physician scepticism is acting as restraints. With respect to regulatory pathways, the system is in place for developed countries. Problem lies with countries such as China, India and Russia that are still trying to device the pathway.

The Key Players profiled in this report include like:

  • Novartis International AG
  • Hospira Inc.
  • Celltrion Pharma Inc.
  • Biocon Limited
  • Teva Pharmaceutical Industries Ltd.

Competitive analysis for biosimilars market is highlighted and market players are outlined and are examined on disparate aspects like company overview coupled with financial overview, product portfolio and recent developments.

Table of Contents

Table of Contents

1. Biosimilars- Market Overview

2. Executive Summary

3. Biosimilars - Market Landscape

  • 3.1. Market Share Analysis
  • 3.2. Comparative Analysis
    • 3.2.1. Product Benchmarking
    • 3.2.2. End user profiling
    • 3.2.3. Top 5 Financials Analysis

4. Biosimilars - Market Forces

  • 4.1. Market Drivers
    • 4.1.1. Economic turmoil in Europe driving demand for biosimilars
    • 4.1.2. 11 biologics to face patent expiration by 2020
    • 4.1.3. FDA keen on introducing more biosimilars into the market
    • 4.1.4. Asian companies have taken advantage by introducing low cost biosimilars
  • 4.2. Market Constraints and Challenges
    • 4.2.1. Stringent Regulatory Scenario
    • 4.2.2. Significant Developmental Cost
    • 4.2.3. Safety and Efficacy poses questions for physician while prescribing biosimilars
  • 4.3. Attractiveness of the Biosimilars Industry
    • 4.3.1. Power of Suppliers
    • 4.3.2. Power of Customers
    • 4.3.3. Threat of New entrants
    • 4.3.4. Threat of Substitution
    • 4.3.5. Degree of Competition

5. Biosimilars Market - Strategic Analysis

  • 5.1. Value Chain Analysis
  • 5.2. Pricing Analysis
  • 5.3. Opportunities Analysis
  • 5.4. Product/Market Life Cycle Analysis
  • 5.5. Suppliers and Distributors

6. Biosimilars Market: By Type

  • 6.1. Recombinant Non-Glycosylated Proteins
  • 6.2. Recombinant Glycosylated Proteins
  • 6.3. Recombinant Peptides Others

7. Biosimilars Market - By Technology

  • 7.1. Monoclonal Antibodies Technology
  • 7.2. Recombinant DNA Technology
  • 7.3. Chromatography
  • 7.4. Nuclear Magnetic Resonance Technology
  • 7.5. Electrophoresis
  • 7.6. Mass Spectrometry
  • 7.7. Western Blotting
  • 7.8. Bioassay

8. Biosimilars Market - By Application

  • 8.1. Blood Disorders
  • 8.2. Oncology Diseases
  • 8.3. Chronic and Autoimmune Diseases
  • 8.4. Growth Hormone Deficiency
  • 8.5. Others

9. Biosimilars Market -Geographic Analysis

  • 9.1. Americas
    • 9.1.1. U.S.
    • 9.1.2. Canada
    • 9.1.3. Brazil
    • 9.1.4. Others
  • 9.2. Europe
    • 9.2.1. France
    • 9.2.2. Germany
    • 9.2.3. U.K.
    • 9.2.4. Italy
    • 9.2.5. Spain
    • 9.2.6. Others
  • 9.3. APAC
    • 9.3.1. China
    • 9.3.2. India
    • 9.3.3. Japan
    • 9.3.4. Australia
    • 9.3.5. Others
  • 9.4. ROW

10. Market Entropy

  • 10.1. New Product Launches
  • 10.2. M&As, Collaborations, JVs and Partnerships

11. Company Profiles

  • 11.1. HOSPIRA INC.
  • 11.2. STADA ARZNEIMITTEL AG
  • 11.3. NOVARTIS
  • 11.4. TEVA PHARMACEUTICAL COMPANY
  • 11.5. DR. REDDY'S LABORATORIES
  • 11.6. CELLTRION PHARMA
  • 11.7. BIOCON LIMITED
  • 11.8. MYLAN N.V.
  • 11.9. JOHNSON & JOHNSON
  • 11.10. DONG-A ST.

More than 40 Companies are profiled in this Research Report, Complete List available on Request*

"*Financials would be provided on a best efforts basis for private companies"

12. Appendix

  • 12.1. Abbreviations
  • 12.2. Sources
  • 12.3. Research Methodology
  • 12.4. Bibliography
  • 12.5. Compilation of Expert Insights
  • 12.6. Disclaimer
Back to Top